SCHEMBL599749

SCHEMBL599749

CC(=O)c1cccc(CBr)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.51
MAOA P21397 2/20 0.47
ALDH1A1 P00352 1/20 0.46
LMNA P02545 2/20 0.46
IL4I1 Q96RQ9 1/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.46
MAPK1 P28482 1/20 0.45
POLB P06746 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPC1 O15118 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL597591 0.85 MAOB (0.49) MAOBMAOAALDH1A1LMNAIL4I1
SCHEMBL3335985 0.83 LMNA (0.59) MAOBMAOAALDH1A1LMNAIL4I1
SCHEMBL2062793 0.83 CES2 (0.48) ALDH1A1CES2CES1MRGPRX4MEN1
SCHEMBL185962 0.83 ATM (0.52) ALDH1A1CES2CES1MEN1KMT2A
SCHEMBL29572523 0.83 ATM (0.52) ALDH1A1CES2CES1MEN1KMT2A
SCHEMBL5915679 0.83 POLB (0.57) MAOBALDH1A1MAPK1POLBMEN1
SCHEMBL40393 0.82 FOLH1 (0.66) CES2CES1MRGPRX4CYP2D6CYP2C9
SCHEMBL1481937 0.82 PRSS1 (0.55) MAOBMAOAALDH1A1LMNAIL4I1
SCHEMBL29964040 0.82 FOLH1 (0.66) CES2CES1MRGPRX4CYP2D6CYP2C9
SCHEMBL7054964 0.82 MAOB (0.53) MAOBMAOAALDH1A1LMNAIL4I1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110305048-A One kind preparing α-sulfuryl ketone compounds synthetic method by α, α-two bromo ketone one kettle way 温州大学 2019-10-08 CN claimed
CN-104788442-A Preparation method of substituted benzoxazole derivative Hunan huateng pharmaceutical co ltd 2015-07-22 CN claimed
CN-103755715-A Benzofuran [2, 3-c] pyridine compound and synthetic method thereof UNIV WUHAN TECH 2014-04-30 CN claimed
EP-1490483-A2 IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS The Scripps Research Institute (US) 2004-12-29 EP claimed
US-20030082575-A1 Translation system for use in the generation of protein containing adjusted amino acid sequences THE SCRIPPS RESEARCH INSTITUTE (US) 2003-05-01 US claimed
WO-2002085923-A2 IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS THE SCRIPPS RESEARCH INSTITUTE (US) 2002-10-31 WO claimed
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 US disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 US disclosed
WO-2025090809-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2025-05-01 WO disclosed
US-11840521-B2 Modulators of Mas-related G-protein receptor X4 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2023-12-12 US disclosed
CN-110869352-B Chemical compound 诺瑟拉有限公司 2023-11-28 CN disclosed
EP-3668881-B1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS INC (US) 2023-10-04 EP disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
WO-2006021418-A1 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2006-03-02 WO disclosed
US-20050250183-A1 In vivo incorporation of unnatural amino acids THE SCRIPPS RESEARCH INSTITUTE (US) 2005-11-10 US disclosed
WO-2005012262-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 WO disclosed
EP-1112998-B1 AMINE DERIVATIVES POLA CHEM IND INC (JP) 2004-12-08 EP disclosed
US-6586633-B1 Antifungal agents POLA CHEMICAL INDUSTRIES, INC. (JP) 2003-07-01 US disclosed
US-20030082575-A1 Translation system for use in the generation of protein containing adjusted amino acid sequences THE SCRIPPS RESEARCH INSTITUTE (US) 2003-05-01 US disclosed
EP-1112998-A1 AMINE DERIVATIVES POLA CHEMICAL INDUSTRIES, INC. (JP) 2001-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11840521-B2 Modulators of Mas-related G-protein receptor X4 and related products and methods MRGPRX4, MRGPRX1, MRGPRX2 MAOB 2818/4885MAOA 2661/4885ALDH1A1 4266/4885
US-20050250183-A1 In vivo incorporation of unnatural amino acids BCAT1, AADAT, NPEPPS MAOB 3992/4885MAOA 3480/4885ALDH1A1 3231/4885
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF GLP1R, GIPR, GCGR MAOB 3569/4885MAOA 3795/4885ALDH1A1 2478/4885
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 MAOB 3798/4885MAOA 4187/4885ALDH1A1 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.